<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The outbreaks of severe" exact="acute" post="respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused"/>
 <result pre="this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The outbreaks of severe acute" exact="respiratory" post="syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by"/>
 <result pre="license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The outbreaks of severe acute respiratory" exact="syndrome" post="(SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV"/>
 <result pre="The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus" exact="Disease" post="2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have"/>
 <result pre="public health and the economy. Treatment and prevention of these" exact="viral" post="diseases call for the research and development of human"/>
 <result pre="cause disease. The 2019 novel coronavirus (SARS-CoV-2), which causes Coronavirus" exact="disease" post="2019 (COVID-19), is the seventh known coronavirus to infect"/>
 <result pre="HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-associated coronavirus (SARS-CoV) and Middle East" exact="Respiratory" post="Syndrome (MERS-CoV). SARS-CoV and MERS-CoV cause very severe symptoms,"/>
 <result pre="HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-associated coronavirus (SARS-CoV) and Middle East Respiratory" exact="Syndrome" post="(MERS-CoV). SARS-CoV and MERS-CoV cause very severe symptoms, while"/>
 <result pre="the other four viruses usually cause only mild to moderate" exact="upper" post="respiratory disease in humans. Severe acute respiratory syndrome (SARS)"/>
 <result pre="other four viruses usually cause only mild to moderate upper" exact="respiratory" post="disease in humans. Severe acute respiratory syndrome (SARS) is"/>
 <result pre="four viruses usually cause only mild to moderate upper respiratory" exact="disease" post="in humans. Severe acute respiratory syndrome (SARS) is a"/>
 <result pre="cause only mild to moderate upper respiratory disease in humans." exact="Severe" post="acute respiratory syndrome (SARS) is a viral respiratory illness"/>
 <result pre="only mild to moderate upper respiratory disease in humans. Severe" exact="acute" post="respiratory syndrome (SARS) is a viral respiratory illness caused"/>
 <result pre="mild to moderate upper respiratory disease in humans. Severe acute" exact="respiratory" post="syndrome (SARS) is a viral respiratory illness caused by"/>
 <result pre="to moderate upper respiratory disease in humans. Severe acute respiratory" exact="syndrome" post="(SARS) is a viral respiratory illness caused by SARS-CoV,"/>
 <result pre="disease in humans. Severe acute respiratory syndrome (SARS) is a" exact="viral" post="respiratory illness caused by SARS-CoV, the first worldwide pandemic"/>
 <result pre="in humans. Severe acute respiratory syndrome (SARS) is a viral" exact="respiratory" post="illness caused by SARS-CoV, the first worldwide pandemic caused"/>
 <result pre="America, Europe, and Asia. As of December 31, 2003, the" exact="total" post="number of SARS cases worldwide had reached 8096, with"/>
 <result pre="fatality rate of about 9.6% (https://www.who.int/csr/sars/country/table2004_04_21/en/). COVID-19 refers to the" exact="respiratory" post="symptoms and pneumonia caused by SARS-CoV-2 infection. By Sep"/>
 <result pre="about 9.6% (https://www.who.int/csr/sars/country/table2004_04_21/en/). COVID-19 refers to the respiratory symptoms and" exact="pneumonia" post="caused by SARS-CoV-2 infection. By Sep 18, 2020, according"/>
 <result pre="in 30,369,778 confirmed cases and 948,795 deaths worldwide (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). The" exact="total" post="number of COVID-19 cases may, however, be higher owing"/>
 <result pre="enzyme 2 (ACE2) Angiotensin-converting enzyme 2 (ACE2) Route of transmission" exact="Respiratory" post="droplets, close contact, fecal-oral route (?) Respiratory droplets, close"/>
 <result pre="Route of transmission Respiratory droplets, close contact, fecal-oral route (?)" exact="Respiratory" post="droplets, close contact, fecal-oral route (?) Incubation period 5"/>
 <result pre="period 5 (2â€&quot;10) days (https://www.who.int/csr/sars/postoutbreak/en/) 5.2 (1.8â€&quot;12.4) days69 Clinical symptoms" exact="Fever" post="(99%), Documented elevated temperature (85%), Nonproductive cough (69%), Myalgia"/>
 <result pre="elevated temperature (85%), Nonproductive cough (69%), Myalgia (49%), Dyspnea (42%)70" exact="Fever" post="(83%), Cough (82%), Shortness of breath (31%), Muscle ache"/>
 <result pre="Dyspnea (42%)70 Fever (83%), Cough (82%), Shortness of breath (31%)," exact="Muscle" post="ache (11%), Confusion (9%), Headache (8%), Sore throat (5%),"/>
 <result pre="Headache (8%), Sore throat (5%), Rhinorrhoea (4%), Chest pain (2%)," exact="Diarrhea" post="(2%), Nausea and vomiting (1%)71 Fatality rate 9.6% ~3.1%a"/>
 <result pre="Diarrhea (2%), Nausea and vomiting (1%)71 Fatality rate 9.6% ~3.1%a" exact="Epidemic" post="area Asia, Europe, North, and South America Globally Epidemic"/>
 <result pre="~3.1%a Epidemic area Asia, Europe, North, and South America Globally" exact="Epidemic" post="time ~8 months Unknown High-risk for severe illness Young"/>
 <result pre="severe illness Young and middle-aged Elderly or frail with underlying" exact="disease" post="Possibility of recurrence Very unlikely Very likely aCalculated based"/>
 <result pre="of recurrence Very unlikely Very likely aCalculated based on the" exact="total" post="number of the confirmed cases and deaths as of"/>
 <result pre="and reagents. Currently, no specific drugs can completely cure the" exact="disease" post="caused by SARS-CoV-2. Therefore, it is urgent to develop"/>
 <result pre="identify antigens, and they have few side effects in humans." exact="Antibody" post="drugs are widely used in many fields, including cancer"/>
 <result pre="humans. Antibody drugs are widely used in many fields, including" exact="cancer" post="and infectious diseases. In addition, antibodies against SARS-CoV and"/>
 <result pre="drugs are widely used in many fields, including cancer and" exact="infectious diseases." post="In addition, antibodies against SARS-CoV and MERS-CoV have been"/>
 <result pre="loop of the RBD core.6 This loop (aa 424â€&quot;494) makes" exact="complete" post="contact with the ACE2 receptor and is called the"/>
 <result pre="S2 subunit gradually approaching each other, narrowing the distance between" exact="viral" post="envelope and host cell membrane; (d, e) HR1 and"/>
 <result pre="host cell membrane to fuse from the hemifusion state to" exact="complete" post="fusion, thus releasing the virus gene into the host."/>
 <result pre="complete fusion, thus releasing the virus gene into the host." exact="Viral" post="genes replicate and translate within cells to produce genomic"/>
 <result pre="replicate and translate within cells to produce genomic RNA and" exact="viral" post="proteins, which are assembled with the proteins to form"/>
 <result pre="viral proteins, which are assembled with the proteins to form" exact="viral" post="particles Fig. 4 Crystal structure of RBD binding to"/>
 <result pre="to the host cell by interfering with the binding of" exact="viral" post="RBD to cellular ACE2 receptor (Fig. 5). These RBD-targeted"/>
 <result pre="510, a region previously identified as the SARS-CoV RBD. Furthermore," exact="complete" post="protection against 100 TCID50 (50% tissue culture infectious dose)"/>
 <result pre="RBD. Furthermore, complete protection against 100 TCID50 (50% tissue culture" exact="infectious" post="dose) of SARS-CoV infectivity was achieved at 42â€‰nM of"/>
 <result pre="to the RBD of the S protein. S230.15 potently inhibited" exact="viral" post="entry into cells and cell fusion mediated by the"/>
 <result pre="protected. Meanwhile, m396 showed significant, but incomplete, protection against SZ16" exact="infection" post="in mice. By analyzing the key residues of m396"/>
 <result pre="in vitro. The NMAb 201 completely protected mice against SARS-CoV" exact="infection" post="at a concentration of 40â€‰mg/kg. In doses as low"/>
 <result pre="RBD of SARS-CoV S protein,23 suggesting that F26G18 neutralizes SARS-CoV" exact="infection" post="by blocking RBD-ACE2 the binding. Using hybridoma technology, 26"/>
 <result pre="of CR3014 IgG and CR3022 IgG may also reduce the" exact="total" post="antibody dose of passive immunity against SARS-CoV infection.26 Transgenic"/>
 <result pre="S protein expressed on the cell surface and inhibit the" exact="infection" post="of SARS-CoV pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml."/>
 <result pre="infection of SARS-CoV pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml." exact="Infection" post="of Vero E6 cells with SARS-CoV was neutralized with"/>
 <result pre="in an ELISA assay.27 NMAb S309 was identified from the" exact="peripheral" post="blood of SARS- infected patients. Neutralization assays showed that"/>
 <result pre="ACE2) for binding to RBD, indicating that ab1 neutralizes SARS-CoV-2" exact="infection" post="by blocking RBD-ACE2 binding. The ab1 IgG1 could completely"/>
 <result pre="by sequence alignment results. This indicates that either natural SARS-CoV-2" exact="infection" post="or RBD-based vaccines could stimulate the quick production of"/>
 <result pre="The results showed that B38 had higher potency to inhibit" exact="viral infection" post="with an IC50 value of 0.177â€‰Î¼g/ml. This was followed"/>
 <result pre="results showed that B38 had higher potency to inhibit viral" exact="infection" post="with an IC50 value of 0.177â€‰Î¼g/ml. This was followed"/>
 <result pre="value of 0.177â€‰Î¼g/ml. This was followed by H4, which inhibited" exact="viral infection" post="with an IC50 value of 0.896â€‰Î¼g/ml. The crystal structure"/>
 <result pre="of 0.177â€‰Î¼g/ml. This was followed by H4, which inhibited viral" exact="infection" post="with an IC50 value of 0.896â€‰Î¼g/ml. The crystal structure"/>
 <result pre="with the RBD-ACE2 binding interface, suggesting that B38 neutralizes SARS-CoV-2" exact="infection" post="by functionally mimicking ACE2 to bind RBD and block"/>
 <result pre="RBD binding in the competition assay. In animal trials, lung" exact="viral" post="load was reduced by 32.8% and 26% with a"/>
 <result pre="neutralization assay, rRBD-15 showed potent neutralization activity against SARS-CoV-2 pseudovirus" exact="infection" post="with an IC50 of 12.2 nM.37 VHH-72 has been"/>
 <result pre="an IC50 value of 8â€‰ng/ml and potently inhibited live SARS-CoV-2" exact="infection" post="with IC50 values of 7 and 9â€‰ng/ml, respectively. To"/>
 <result pre="these B cells were then sequenced, and then expressed as" exact="complete" post="antibodies. Finally, about 40 antibodies with unique sequences and"/>
 <result pre="showed that this noncompetitive antibody cocktail therapy can effectively avoid" exact="viral" post="escape mutations.43 A single-domain antibody H11 that specifically binds"/>
 <result pre="assay showed that H11-H4-Fc and H11-D4-Fc could neutralize live SARS-CoV-2" exact="infection" post="with the ND50 of 6â€‰nM and 18â€‰nM, respectively. Combining"/>
 <result pre="a phage display antibody library generated from RNAs extracted from" exact="peripheral" post="lymphocytes of mice immunized with SARS-CoV RBD, which could"/>
 <result pre="levels. H014 IgG could effectively neutralize SARS-CoV-2 and SARS-CoV pseudovirus" exact="infection" post="with IC50 of 3 and 1â€‰nM respectively, and can"/>
 <result pre="most potent NMAb 2â€&quot;15 could neutralize pseudotyped and live SARS-CoV-2" exact="infection" post="with IC50 of 5â€‰ng/ml and 0.7â€‰ng/ml, respectively, by binding"/>
 <result pre="S protein expressed on the cell surface and inhibit the" exact="infection" post="of SARS-CoV-2 pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml."/>
 <result pre="infection of SARS-CoV-2 pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml." exact="Infection" post="of Vero E6 cells with SARS-CoV-2 was neutralized with"/>
 <result pre="attempted to identify NMAbs with cross-reactivity for SARS-CoV-2 from the" exact="peripheral" post="blood of SARS-infected patients. In order to detect the"/>
 <result pre="of NMAbs against SARS-CoV-2, pseudovirus neutralization assays with a murine" exact="leukemia" post="virus (MLV) pseudotyping system were performed. Results showed that"/>
 <result pre="the future is unknown. With the third pandemic of coronavirus" exact="pneumonia" post="caused by SARS-CoV-2, this reminds us that the answer"/>
 <result pre="we need to develop prophylactic and therapeutic drugs against coronavirus" exact="infection" post="as soon as possible. Antibody drugs with the characteristics"/>
 <result pre="and therapeutic drugs against coronavirus infection as soon as possible." exact="Antibody" post="drugs with the characteristics of precise targeting, few side"/>
 <result pre="protection of mice: 4/4 mice with &amp;gt;4â€‰log reduction in lung" exact="viral" post="load at 12.5â€‰mg/kg. CR3014 scFv Human Semisynthetic antibody phage"/>
 <result pre="at 42â€‰nM; 15,16 Protection of ferrets: 10â€‰mg/kg. 1A5 2C5 IgG" exact="Mouse" post="Animal immunization; hybridoma technology 310â€&quot;535 LV neutralization: IC50â€‰=â€‰0.71â€‰Âµg/ml. 17"/>
 <result pre="immunization; hybridoma technology 460â€&quot;476 LV neutralization: titerâ€‰=â€‰2.07â€‰nM. 22,23 341â€‰C IgG" exact="Mouse" post="Animal immunization; hybridoma technology 490â€&quot;510 LV neutralization: ND100 at"/>
 <result pre="patients RBD LV neutralization: IC50â€‰=â€‰0.177â€‰Âµg/ml; 34 Protection of mice: Lung" exact="viral" post="load reduced by 32.8% compared with PBS control. H4"/>
 <result pre="patients RBD LV neutralization: IC50â€‰=â€‰0.896â€‰Âµg/ml; 34 Protection of mice: Lung" exact="viral" post="load reduced by 26% compared with PBS control. 7B11"/>
 <result pre="reduced by 26% compared with PBS control. 7B11 18F3 IgG" exact="Mouse" post="Animal immunization; hybridoma technology RBD PsV neutralization: IC80â€‰=â€‰10â€‰Î¼g/ml. 35"/>
 <result pre="IC50â€‰=â€‰0.019â€‰Î¼g/ml; 39 LV neutralization: IC50â€‰=â€‰0.022â€‰Î¼g/ml; Full protection of Syrian hamsters:" exact="Antibody" post="serum concentration of ~22â€‰Âµg/ml. COVA1-18 COVA2-15 IgG Human B"/>
 <result pre="PsV neutralization: IC50â€‰=â€‰3â€‰nM; LV neutralization: IC50â€‰=â€‰38â€‰nM; Protection of mice: Lung" exact="viral" post="load reduced by about 10 ~100 folds compared with"/>
 <result pre="PsV neutralization: IC50â€‰=â€‰0.7â€‰ng/ml; 48 LV neutralization: IC50â€‰=â€‰5â€‰ng/ml; Protection of hamsters:" exact="Viral" post="RNA copy numbers and infectious virus titers in lung"/>
 <result pre="neutralization: IC50â€‰=â€‰5â€‰ng/ml; Protection of hamsters: Viral RNA copy numbers and" exact="infectious" post="virus titers in lung tissues were reduced by 4"/>
 <result pre="more compared with PBS control. CR3022 IgG Human Gene cloning;" exact="Protein" post="expression RBD LV neutralization: IC50â€‰=â€‰~â€‰0.114â€‰Î¼g/ml. 55 4A8 IgG Human"/>
 <result pre="receptor-binding domain complexed with receptorScience20053091864186816166518 7.HeYet al.Receptor-binding domain of severe" exact="acute" post="respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes"/>
 <result pre="domain complexed with receptorScience20053091864186816166518 7.HeYet al.Receptor-binding domain of severe acute" exact="respiratory" post="syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that"/>
 <result pre="complexed with receptorScience20053091864186816166518 7.HeYet al.Receptor-binding domain of severe acute respiratory" exact="syndrome" post="coronavirus spike protein contains multiple conformation-dependent epitopes that induce"/>
 <result pre="induces protective immunity. Nature (2020). 13.SuiJet al.Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
 <result pre="protective immunity. Nature (2020). 13.SuiJet al.Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
 <result pre="immunity. Nature (2020). 13.SuiJet al.Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
 <result pre="al.Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe" exact="acute" post="respiratory syndrome by an animal study, epitope mapping, and"/>
 <result pre="of human monoclonal antibody 80R for immunoprophylaxis of severe acute" exact="respiratory" post="syndrome by an animal study, epitope mapping, and analysis"/>
 <result pre="human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory" exact="syndrome" post="by an animal study, epitope mapping, and analysis of"/>
 <result pre="antibodies binding to the spike and nucleocapsid proteins of severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.2005791635164415650189 16.ter MeulenJet al.Human monoclonal antibody"/>
 <result pre="binding to the spike and nucleocapsid proteins of severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.2005791635164415650189 16.ter MeulenJet al.Human monoclonal antibody as"/>
 <result pre="to the spike and nucleocapsid proteins of severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.2005791635164415650189 16.ter MeulenJet al.Human monoclonal antibody as prophylaxis"/>
 <result pre="16.ter MeulenJet al.Human monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferretsLancet20043632139214115220038 17.ChouTHet al.Epitope mapping and biological function analysis"/>
 <result pre="immunization of mice with an inactivated Chinese isolate of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV)Virology200533413414315749129 18.ZhuZet al.Potent cross-reactive neutralization of"/>
 <result pre="of mice with an inactivated Chinese isolate of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV)Virology200533413414315749129 18.ZhuZet al.Potent cross-reactive neutralization of SARS"/>
 <result pre="monoclonal antibodiesProc. Natl Acad. Sci. USA.2007104121231212817620608 19.PrabakaranPet al.Structure of severe" exact="acute" post="respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibodyJ."/>
 <result pre="antibodiesProc. Natl Acad. Sci. USA.2007104121231212817620608 19.PrabakaranPet al.Structure of severe acute" exact="respiratory" post="syndrome coronavirus receptor-binding domain complexed with neutralizing antibodyJ. Biol."/>
 <result pre="Natl Acad. Sci. USA.2007104121231212817620608 19.PrabakaranPet al.Structure of severe acute respiratory" exact="syndrome" post="coronavirus receptor-binding domain complexed with neutralizing antibodyJ. Biol. Chem.2006281158291583616597622"/>
 <result pre="antibodyJ. Biol. Chem.2006281158291583616597622 20.GreenoughTCet al.Development and characterization of a severe" exact="acute" post="respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective"/>
 <result pre="Biol. Chem.2006281158291583616597622 20.GreenoughTCet al.Development and characterization of a severe acute" exact="respiratory" post="syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis"/>
 <result pre="neutralizing and antibodies reactive to S, N, M and E" exact="viral" post="proteinsJ. Virological Methods20051282128 25.WrappDet al.Structural basis for potent neutralization"/>
 <result pre="blood residential time in APP/PS1 mice but does not increase" exact="brain" post="uptakeNucl. Med. Biol.20154269570225960433 31.CaoYet al.Potent neutralizing antibodies against SARS-CoV-2"/>
 <result pre="39.RogersTFet al.Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from" exact="disease" post="in a small animal modelScience202036995696332540903 40.BrouwerPJMet al.Potent neutralizing antibodies"/>
 <result pre="the prefusion conformationScience20203671260126332075877 52.WuFet al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526932015508 53.TianXet al.Potent binding of 2019 novel"/>
 <result pre="prefusion conformationScience20203671260126332075877 52.WuFet al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526932015508 53.TianXet al.Potent binding of 2019 novel coronavirus"/>
 <result pre="of SARS-CoV-2Science202036965065532571838 57.MulanguSet al.A randomized, controlled trial of ebola virus" exact="disease" post="therapeuticsN. Engl. J. Med.20193812293230331774950 58.SteinitzMKleinGKoskimiesSMakelOEB virus-induced B lymphocyte cell"/>
 <result pre="59.KozborDRoderJCRequirements for the establishment of high-titered human monoclonal antibodies against" exact="tetanus" post="toxoid using the Epstein-Barr virus techniqueJ. Immunol.1981127127512806268704 60.KarpasADremuchevaACzepulkowskiBHA human"/>
 <result pre="tetanus toxoid using the Epstein-Barr virus techniqueJ. Immunol.1981127127512806268704 60.KarpasADremuchevaACzepulkowskiBHA human" exact="myeloma" post="cell line suitable for the generation of human monoclonal"/>
 <result pre="receptor-binding domain. Preprint at 10.1101/2020.04.16.045419 (2020). 68.LiuPet al.Are pangolins the" exact="intermediate" post="host of the 2019 novel coronavirus (SARS-CoV-2)?PLoS Pathog.202016e100842132407364 69.ZhangJet"/>
 <result pre="(SARS-CoV-2)?PLoS Pathog.202016e100842132407364 69.ZhangJet al.Evolving epidemiology and transmission dynamics of coronavirus" exact="disease" post="2019 outside Hubei province, China: a descriptive and modelling"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet202039550751332007143"/>
</results>
